口腔鳞状细胞癌（OSCC）的治疗仍然是一个重大困难，因为过去五十年来生存率没有提高。因此，探索和确认新的可靠的治疗靶点和生物标志物对于口腔鳞癌的治疗势在必行。 TEAD 转录因子对于整合和协调多个信号通路至关重要，这些信号通路对于胚胎发育、器官形成和组织稳态至关重要。此外，通过附着于共激活剂，TEAD 可以改变 Cyr61、Myc 和结缔组织生长因子等基因的表达，从而促进肿瘤进展。因此，TEAD 被认为是一种有效的预测生物标志物，因为它与包括 OSCC 在内的多种恶性肿瘤的临床参数存在显着相关性。专门针对 TEAD 的现有药物的疗效已显示出令人鼓舞的结果，表明其作为 OSCC 治疗的最佳靶点的潜力。本综述通过强调 TEAD 的转录机制和致癌信号通路的参与，概述了当前 OSCC 的靶向治疗策略。最后，对利用 TEAD 作为解决 OSCC 的创新方法的可行性及其潜在的临床应用进行了分析和讨论。版权所有 © 2024 Wang、Shao、Gao、Zhao、Kong、Deng、Yang、Shang、Sun 和 Fu。

The treatment of oral squamous cell carcinoma (OSCC) remains a significant difficulty, as there has been no improvement in survival rates over the past fifty years. Hence, exploration and confirmation of new dependable treatment targets and biomarkers is imperative for OSCC therapy. TEAD transcription factors are crucial for integrating and coordinating multiple signaling pathways that are essential for embryonic development, organ formation, and tissue homeostasis. In addition, by attaching to coactivators, TEAD modifies the expression of genes such as Cyr61, Myc, and connective tissue growth factor, hence facilitating tumor progression. Therefore, TEAD is regarded as an effective predictive biomarker due to its significant connection with clinical parameters in several malignant tumors, including OSCC. The efficacy of existing drugs that specifically target TEAD has demonstrated encouraging outcomes, indicating its potential as an optimal target for OSCC treatment. This review provides an overview of current targeted therapy strategies for OSCC by highlighting the transcription mechanism and involvement of TEAD in oncogenic signaling pathways. Finally, the feasibility of utilizing TEAD as an innovative approach to address OSCC and its potential clinical applications were analyzed and discussed.Copyright © 2024 Wang, Shao, Gao, Zhao, Kong, Deng, Yang, Shang, Sun and Fu.